A Novel Combination Therapy Tβ4/VIP Protects against Hyperglycemia-Induced Changes in Human Corneal Epithelial Cells
Abdul Shukkur Ebrahim1, Thomas W Carion1, Thanzeela Ebrahim1
1Department of Ophthalmology, Visual & Anatomical Sciences, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Abstract:
Despite the prevalence of diabetic retinopathy, the majority of adult diabetic patients develop visually debilitating corneal complications, including impaired wound healing. Unfortunately, there is limited treatment for diabetes-induced corneal damage. The current project investigates a novel, peptide-based combination therapy, thymosin beta-4 and vasoactive intestinal peptide (Tβ4/VIP), against high-glucose-induced damage to the corneal epithelium. Electric cell-substrate impedance sensing (ECIS) was used for real-time monitoring of barrier function and wound healing of human corneal epithelial cells maintained in either normal glucose (5 mM) or high glucose (25 mM) ± Tβ4 (0.1%) and VIP (5 nM). Barrier integrity was assessed by resistance, impedance, and capacitance measurements. For the wound healing assay, cell migration was also monitored. Corneal epithelial tight junction proteins (ZO-1, ZO-2, occludin, and claudin-1) were assessed to confirm our findings. Barrier integrity and wound healing were significantly impaired under high-glucose conditions. However, barrier function and cell migration significantly improved with Tβ4/VIP treatment. These findings were supported by high-glucose-induced downregulation of tight junction proteins that were effectively maintained similar to normal levels when treated with Tβ4/VIP. These results strongly support the premise that Tβ4 and VIP work synergistically to protect corneal epithelial cells against hyperglycemia-induced damage. In addition, this work highlights the potential for significant translational impact regarding the treatment of diabetic patients and associated complications of the cornea.
Insights
A new peptide therapy combining thymosin beta-4 (Tβ4) and vasoactive intestinal peptide (VIP) shows promise for treating diabetic corneal damage. This Tβ4/VIP treatment improved barrier function and wound healing in human corneal cells exposed to high glucose.
Area of Science:
- Ophthalmology
- Endocrinology
- Regenerative Medicine
Background:
- Diabetic retinopathy is common, but corneal complications like impaired wound healing significantly impact vision in adult diabetic patients.
- Effective treatments for diabetes-induced corneal damage are limited, necessitating novel therapeutic strategies.
Purpose of the Study:
- To investigate a novel peptide combination therapy, thymosin beta-4 (Tβ4) and vasoactive intestinal peptide (VIP), for high-glucose-induced corneal epithelial damage.
- To assess the protective effects of Tβ4/VIP on corneal epithelial barrier function and wound healing under hyperglycemic conditions.
Main Methods:
- Human corneal epithelial cells were cultured in normal (5 mM) or high (25 mM) glucose conditions.
- Electric cell-substrate impedance sensing (ECIS) monitored barrier integrity (resistance, impedance, capacitance) and cell migration for wound healing.
- Expression of tight junction proteins (ZO-1, ZO-2, occludin, claudin-1) was analyzed.
Main Results:
- High glucose significantly impaired corneal epithelial barrier integrity and wound healing.
- Treatment with Tβ4/VIP synergistically improved barrier function and accelerated cell migration in high-glucose conditions.
- Tβ4/VIP treatment maintained tight junction protein levels, counteracting high-glucose-induced downregulation.
Conclusions:
- The Tβ4/VIP peptide combination therapy effectively protects corneal epithelial cells against hyperglycemia-induced damage.
- This synergistic therapy demonstrates significant potential for treating corneal complications in diabetic patients.
- Further translational research is warranted to explore Tβ4/VIP as a therapeutic option for diabetic eye disease.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones